Patients sought for Phase 2 trial of SAGE-718 for cognitive problems
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild…
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild…
Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for…
A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now…
A small group of people with Parkinson’s disease adhered well to an experimental music-based digital therapy to treat gait…
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on…
Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people…
People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more…
A 12-week electroacupuncture (EA) regimen in Parkinson’s disease patients along with standard medications was well tolerated and led to…
Get regular updates to your inbox.